scholarly journals Age and Lymph Nodes Examination May Be Related to the Outcome of Ovarian Clear Cell Carcinoma: A SEER Analysis

2021 ◽  
Author(s):  
Menghan Zhu ◽  
Nan Jia ◽  
Wei Jiang
Keyword(s):  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Proportional Hazards ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Cox Proportional Hazards ◽  
Stage I ◽  
Stage Iii ◽  
Ovarian Clear Cell Carcinoma ◽  
Significant Difference

Abstract AimTo analyze and compare the demographics, treatment, and survival rates in patients with ovarian clear cell carcinoma (OCCC).MethodsWe conducted a population-based retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1998 to 2016. Data of 4344 women with OCCC were compared, and survival was analyzed using the Kaplan–Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model.ResultsThere was no significant difference in cause specific survival (CSS) regardless of chemotherapy in stage I and stage II OCCC. In women with stage III/IV OCCC, there was an increased mortality in women without chemotherapy (5-year CSS 29.80% vs. 24.90%, p<0.001). Among stage I women younger than 60 years old, the 5-year CSS of those underwent chemotherapy was worse than that of non-chemotherapy (86.4% vs. 97.50%, p=0.002). Among these patients, omitting chemotherapy had improved CSS (HR 0.539; 95% CI 0.386-0.753), and omitting lymph nodes examination had decreased CSS (HR 1.666; 95% CI 1.230-2.256). In stage III/IV women who were 60 years or older, the 5-year CSS of those underwent chemotherapy was better than that of non-chemotherapy (32.60% vs. 24.30%, p<0.001). Among these patients, omitting chemotherapy (HR 1.769; 95% CI 1.385-2.258) and omitting lymph nodes examination (HR 1.709; 95% CI 1.371-2.130) had lower CSS.ConclusionChemotherapy has different effects in patients with OCCC at different stages and ages. Age and lymph nodes examination may be factors that affect the outcome of patients with OCCC.

Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma

2018 ◽  
Vol 23 (5) ◽  
pp. 930-935 ◽  
Author(s):  
Yuji Takei ◽  
Suzuyo Takahashi ◽  
Shizuo Machida ◽  
Akiyo Taneichi ◽  
Takahiro Yoshiba ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Recurrence Free Survival ◽  
Ovarian Clear Cell Carcinoma ◽  
Free Survival

scholarly journals Clinical Characteristics and Prognosis of Ovarian Clear Cell Carcinoma: a Retrospective Study of 112 Patients in Beijing

2020 ◽  
Author(s):  
Huimei Zhou ◽  
Qian Liu ◽  
Xiaohua Shi ◽  
Jiaxin Yang ◽  
Dongyan Cao ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Stage Iii ◽  
Ca 125 ◽  
Ovarian Clear Cell Carcinoma

Abstract ObjectivesThis retrospective study aimed to evaluate the clinical characteristics and prognosis of ovarian clear cell carcinoma (OCCC) and to further explore the monitoring value of cancer antigen 125 (CA-125).MethodsThe medical records of 112 OCCC patients who were treated in Peking Union Medical College Hospital (PUMCH) between 2014 and 2019 were collected and reviewed, and data such as age, Federation of Gynecology and Obstetrics (FIGO) stage, CA-125 level, treatment, recurrence, and death were extracted.OutcomesThe median patient age was 50 (45, 57) years. Sixty (53.57%) patients were in stage I, 13 (11.61%) patients were in stage II, 22 (28.57%) patients were in stage III, and 7 (6.25%) patients were in stage IV. In total, 109 (97.32%) patients received adjuvant chemotherapy. The median chemotherapy cycles of CA-125 normalization was 2 (0, 3). The 1-year and 3-year progression-free survival (PFS) rates were 87.85% and 72.90%, respectively. The median PFS1 duration was 19 (11, 35) months, and the median overall survival (OS) duration was 24 (13, 40) months. Recurrence occurred in 32 patients, of whom 7 (21.88%) developed platinum-resistant recurrence. Fifty percent of relapsed patients had a CA-125 level<35 IU/ml at the time of relapse. Nine (28.13%) patients experienced a second recurrence. In the multivariate Cox regression analysis, the Chemotherapy cycles of CA-125 normalization remained nonsignificant for stage I (P=0.003, HR 4.287, 95% CI=1.632–11.258) and stage III (P=0.003, HR 4.287, 95% CI=1.632–11.258) disease. Multivariate Cox regression showed that platinum resistance was an independent factor for PFS2 (P=0.008, HR 11.562, 95% CI=1.873–71.353).ConclusionsFIGO stage and chemotherapy resistance are independent risk factors for prognosis. CA-125 levels following treatment are a valid indicator for treatment monitoring. Regardless of chemosensitivity to CA-125, CA-125 normalization before chemotherapy cycle 2 may not be a distinct inflection point for PFS and OS.

Recurrence factors of stage I ovarian clear cell carcinoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16577-e16577
Author(s):  
Yuji Takei ◽  
Hiroyuki Fujiwara ◽  
Shizuo Machida ◽  
Akiyo Taneichi ◽  
Suzuyo Takahashi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Ovarian Clear Cell Carcinoma

Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma: Is it Necessary for Stage IA?

2012 ◽  
Vol 22 (7) ◽  
pp. 1143-1149 ◽  
Author(s):  
Mika Mizuno ◽  
Hiroaki Kajiyama ◽  
Kiyosumi Shibata ◽  
Kimio Mizuno ◽  
Osamu Yamamuro ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Stage I ◽  
Surgical Staging ◽  
Recurrence Free Survival ◽  
Ovarian Clear Cell Carcinoma ◽  
Free Survival ◽  
Stage Ia

BackgroundIt is controversial whether patients with stage I ovarian clear cell carcinoma (CCC) benefit from postoperative chemotherapy. This study was designed to evaluate the postoperative outcomes associated with the inclusion or exclusion of adjuvant therapy in these patients.MethodsA total of 185 patients who were treated for stage I CCC between 1991 and 2007 were retrospectively evaluated. All of the patients had received comprehensive surgical staging, and their condition had been diagnosed by a central pathological review system. Only one patient with stage IB was excluded from this study.ResultsMedian follow-up time was 62 months (range 7–191 months). Median age was 52 years (30–75 years). There were 41, 93, and 50 patients in stage IA, intraoperative capsule ruptured IC (rupture-IC), and all other-IC groups, respectively. The 5-year recurrence-free survival rates for the substage were 97.6%, 87.8%, and 70.4% (P < 0.001), respectively. Among 134 patients consisting of those in the stage IA and rupture-IC groups, 91 patients received adjuvant chemotherapy (AC) and 43 patients did not (non-AC). There was no significant survival difference in each substage group between the non-AC and AC groups in 5-year recurrence-free survival rate (stage IA, 100% vs 93.8%; rupture-IC, 94.1% vs 86.6%). Multivariate analysis demonstrated that there was no significant prognostic factor for both recurrence and survival among the IA and rupture-IC groups. Postoperative therapy, regimen, and chemotherapy cycles were not significantly affected.ConclusionsThis study indicates that adjuvant chemotherapy does not contribute to the improving prognosis of stage IA ovarian CCC. Whereas the histological type is CCC, the routine adjuvant chemotherapy after comprehensive surgical staging may be unnecessary for patients with at least stage IA.

scholarly journals Predictors and survival of Primary clear cell carcinoma of liver: a population-based study of an uncommon primary liver tumor

2020 ◽  
Author(s):  
Jie Wen ◽  
Abudureyimujiang Aili ◽  
xueyan yao ◽  
Junjie Wang ◽  
li xiang xue
Keyword(s):  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Proportional Hazards ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Cox Proportional Hazards ◽  
Pathological Grade ◽  
Primary Liver Tumor ◽  
Risk Of Death ◽  
Ajcc Stage

Abstract Background: The clinicopathological features and prognostic factors of primary clear cell carcinoma of the liver (PCCCL) remain unknown. Aims: We aimed to determine the clinical, pathological, demographic, and therapeutic characteristics of PCCCL and the effects of these factors on the prognosis. Methods: Patients were selected from the "Surveillance, Epidemiology and End Results" (SEER) database. Data were analyzed with the Kaplan-Meier, Cox proportional hazards regression, and multivariate ordinal regression analyses. Results: We included 248 PCCCL patients with an average age of 64.1 years. The majority (50.4%) had low pathological grade (grade I/II). The 3-, 5-, and 10-year overall survival (OS) probabilities and disease-specific survival (DSS) rates were 33.8%, 23.2%, 12.2%, and 39.8%, 28.3%, 19.1%, respectively. The widowed patients (OS, P=0.271; DSS, P=0.022) with tumor ≥ 1 cm (OS, P=0.001; DSS, P=0.002) had a higher risk of death. Uninsurance and medicaid were independently associated with a shorter survival (OS, P=0.029; DSS, P=0.017). Among surgical means, total proctectomy along with total colectomy, and wedge or segmental resection/partial proctosigmoidectomy were more beneficial to PCCCL. The black PCCCL patients had a poorer survival than the white group. Furthermore, pathological grade I PCCCL was more likely to present AJCC stage I (P=0.005, OR=-1.062). Conclusion: PCCCL patients had a poor outcome. PCCCL was inclined to be localized, male-prevalent and lower pathological grade. Insurance, tumor size, and marital status were independent prognostic factors for OS and DSS, whereas race affected only OS. Surgery could improve OS and DSS. Moreover, highly differentiated PCCCL was susceptible to early AJCC stage.

scholarly journals Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy

2021 ◽  
Vol 19 (2) ◽  
pp. 172-180
Author(s):  
Soumyajit Roy ◽  
Paul Hoskins ◽  
Anna Tinker ◽  
Harinder Brar ◽  
Gale Bowering ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Adjuvant Treatment ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Final Analysis ◽  
Population Based ◽  
Ovarian Clear Cell Carcinoma ◽  
Population Based Study ◽  
Significant Difference

Background: Adjuvant treatment in early ovarian clear cell carcinoma (OCCC) is not yet standardized. The objective of this population-based study was to compare the outcome of patients with early OCCC treated with adjuvant chemotherapy versus chemoradiotherapy (chemoRT) and evaluate the association of adjuvant radiotherapy regimens (whole abdominal radiotherapy [WART] versus pelvic nodal radiotherapy [PRT]) with outcome. Patients and Methods: Chart review was conducted to identify patients with stage I and II OCCC with complete information on staging. Patients with stage IA, IB, or IC OCCC purely resulting from capsular rupture were excluded because the provincial protocol does not recommend adjuvant treatment. Results: Overall, 403 patients were identified and 343 received adjuvant treatment, of whom 255 had stage IC or II OCCC and 153 were eligible for final analysis. On Cox multivariable regression, receipt of chemoRT (n=90) was associated with an improvement in failure-free survival (FFS) (hazard ratio [HR], 0.57; 95% CI, 0.34–0.94) compared with chemotherapy alone (n=63). Use of chemoRT also resulted in 54% reduction in the cumulative incidence of cancer-specific mortality (subdistribution HR, 0.46; 95% CI, 0.24–0.89). However, there was no significant difference in the HR for overall survival (OS) between the chemoRT (HR, 0.70; 95% CI, 0.43–1.13) and chemotherapy group. Relative to chemotherapy + WART (chemo-WART), chemotherapy + PRT (chemo-PRT) was not associated with any significant difference in HR for FFS (HR, 1.34; 95% CI, 0.40–4.44) or OS (HR, 1.13; 95% CI, 0.37–3.46). Conclusions: Adjuvant chemoRT was associated with a lower risk of failure compared with chemotherapy alone. However, there was no difference in OS between the adjuvant chemotherapy and chemoRT regimens. Additionally, no significant difference in terms of FFS or OS was found between the chemo-WART and chemo-PRT groups.

scholarly journals Clinical Characteristics and Prognosis of Ovarian Clear Cell Carcinoma: A 10-Year Retrospective Study

2020 ◽  
Author(s):  
Chenchen Zhu ◽  
Jing Zhu ◽  
Lili Qian ◽  
Hanyuan Liu ◽  
Zhen Shen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Clinical Characteristics ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Supporting Evidence ◽  
Ovarian Clear Cell Carcinoma ◽  
Positive Lymph Nodes

Abstract Background Ovarian clear cell carcinoma (OCCC) is a special pathological type of epithelial ovarian carcinoma (EOC), we conducted this research in order to investigate the clinical characteristics and outcomes of OCCC and to provide additional supporting evidence to aid in the clinical diagnosis and management. Methods This was a retrospective study investigating the clinical characteristics and survival outcomes of 87 patients with OCCC treated at our center between January 2010 and March 2020. Survival analysis was also performed on 179 patients with OCCC obtained from the Surveillance, Epidemiology and End Results (SEER) cancer registry database. Results The median age of participants was 49.28 ± 9.8 years old, with 74.71% diagnosed at early stage. Median CA125 level was 607.26 IU/mL, with 23.94% having normal CA125 levels. 16 patients (18.39%) had co-existing endometriosis and 8 patients (9.2%) developed venous thromboembolism (VTE). There were 5 patients received suboptimal cytoreduction. 67 patients (77.01%) underwent lymphadenectomy, and only 3 (4.48%) were found to have positive lymph nodes. Patients diagnosed at an early stage had higher 3-year overall survival (OS) and progression-free survival (PFS) rates than those with advanced stage OCCC. CA199 (P = 0.025) and ascites (P = 0.001) were significantly associated with OS, while HE4 (P = 0.027) and ascites (P = 0.001) were significantly associated with PFS. Analysis of data from the SEER database showed that positive lymph nodes is also an independent prognostic factor for OS (P = 0.001). Conclusions OCCC often presents at an early stage and young age with a mildly elevated CA125. CA199, HE4, massive ascites and positive lymph node are independent prognostic factors.

Sign in / Sign up

Export Citation Format

Share Document